Maeda K, Ushijima H, Shimamoto T, Shigematsu T, Kurano A, Watanabe Y, Jimi S, Okadome M, Mashiba H
Department of Gynecology, National Kyushu Cancer Center, Fukuoka.
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Dec;41(12):1896-902.
The 6-day subrenal capsule assay (SRC) in normal immuno-competent mice was used to test the responsiveness of ovarian cancer to combination chemotherapy and assess the usefulness of SRC in clinical application. A total of 18 different patients in 22 different assays were studied. Twenty-one assays (95%) were evaluable. The predictive sensitivity was 50%, the predictive resistance 75% and the predictive total accuracy 55% respectively. Sensitive drugs in repeated assays in four patients were not changed. Etoposide, cyclophosphamide, cis-platin and adriamycin were sensitive. Etoposide was the most sensitive of four drugs. The response rate was 50% in the patients treated with etoposide as the first line chemotherapy and the second line chemotherapy, respectively. Patients who were treated with sensitive drugs in SRC survived longer than the patients treated with cis-platin combined chemotherapy without etoposide. The median survival time was 19 months and the mean progression free interval was 15 months. In the results of this study, the value of SRC was supported by the results of chemosensitivity tests and etoposide seems useful in chemotherapy in ovarian cancer.
在正常免疫功能小鼠中进行为期6天的肾包膜下测定（SRC），以测试卵巢癌对联合化疗的反应性，并评估SRC在临床应用中的实用性。在22次不同测定中，共研究了18例不同患者。21次测定（95%）可评估。预测敏感性、预测耐药性和预测总准确率分别为50%、75%和55%。4例患者重复测定中的敏感药物未发生变化。依托泊苷、环磷酰胺、顺铂和阿霉素敏感。依托泊苷是这四种药物中最敏感的。分别以依托泊苷作为一线化疗和二线化疗的患者，缓解率均为50%。在SRC中接受敏感药物治疗的患者比接受不含依托泊苷的顺铂联合化疗的患者存活时间更长。中位生存时间为19个月，平均无进展生存期为15个月。在本研究结果中，化疗敏感性测试结果支持了SRC的价值，依托泊苷似乎在卵巢癌化疗中有用。
